Evaluating the efficacy of treatment with therapeutic antibodies can involve a combination of assays to measure:
- Pharmacokinetics – the levels of the drug
- Pharmacodynamics – e.g. biomarker analysis of the drug target
- Immunogenicity development – anti-drug antibodies (ADA), and neutralizing antibodies
This data is also needed when investigating lack of response to biotherapeutics, or when comparing the performance of biosimilars to reference products. There are clear advantages in running such assays on the same samples in the same run. Gyrolab® xPand system was used to run three assays (pharmacokinetics of infliximab, the biomarker TNF-α, and ADA) in the same 3-CD run. Gyrolab Manager enabled the setup of the three immunoassays, including mapping the samples to the different assays, and Gyrolab Evaluator was used to evaluate the results, which were ready 3 h after starting the run.
Find out more about the evaluation of therapeutic antibody performance with multiple nanolitre-scale immunoassays in this poster from Gyros Protein Technologies. To view the poster, please click here!
For more information on Gyros Protein Technologies, please click here!